Extracorporeal shock waves effectively suppress colorectal cancer proliferation and growth

Your study provides significant insights into the application of extracorporeal shock waves (ESV) as a therapeutic approach for colorectal cancer. By focusing on the differential effects of varying ESV energy levels, the research identifies 60 mJ ESV as the optimal dosage for suppressing tumor growth without adverse effects on body weight or organ function, making it a particularly promising candidate for clinical applications.

The findings that 60 mJ ESV suppressed cancer cell proliferation and induced apoptosis and ferroptosis by activating the p53 signaling pathway offer a mechanistic explanation for its efficacy. The use of transcriptome analysis, complemented by immunohistochemical staining and western blotting, reinforces the robustness of these conclusions. The observed activation of p53 signaling as a driver of both apoptosis and ferroptosis highlights the pathway’s dual role in halting cancer progression.

This research not only advances our understanding of the biological impact of ESV but also underscores its therapeutic potential as a non-invasive treatment strategy. The ability of MI-773 to effectively delay tumor growth while preserving systemic health positions it as a novel and promising modality for treating colorectal cancer. Further exploration into its mechanisms and clinical translation could open up new horizons in cancer therapy.